

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫療控股有限公司

China Resources Medical Holdings Company Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

PROFIT WARNING

This announcement is made by China Resources Medical Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the announcement issued by the Company dated February 21, 2025 (the “**Announcement**”) in relation to the Yan Hua IOT Agreement Dispute. Unless otherwise defined, capitalized terms used herein shall have the same meanings given to them in the Announcement.

The board (the “**Board**”) of directors of the Company (the “**Director(s)**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that the Company is in the course of preparing its consolidated financial results for the six months ended June 30, 2025 (the “**Reporting Period**”). Based on information currently available to the Company and the preliminary review of the Group’s unaudited consolidated management accounts for the Reporting Period, the Company expects that the profit attributable to the owners of the Company for the Reporting Period would record a decrease of approximately 20% to 25% as compared to the corresponding period in 2024; whereas, after excluding the one-off compensation for the management fees in previous years and the supply chain loss under the Yan Hua IOT Agreement of approximately RMB210 million received by the Group as stated in the Announcement and the corresponding enterprise income tax, the profit attributable to the owners of the Company would decrease by approximately 55% to 60% as compared to the corresponding period in 2024. Such expected decrease in profit is mainly attributable to the decrease in operating profits of member medical institutions which is in turn caused by a decrease in average medical insurance fee per visit. At the same time, the Company has been gradually withdrawing from IOT (the “invest-operate-transfer” model) business, the corresponding profit contribution of which has decreased. In the second half of 2025, the Company will continue to proactively improve the revenue structure, promote management refinement and control operating costs in order to increase operating performance.

The Company is still in the process of finalising the Group's consolidated financial statements for the Reporting Period. The information contained in this announcement is only based on the information currently available to the Company and the preliminary assessment with reference to the unaudited consolidated management accounts of the Group for the Reporting Period, which are yet to be reviewed by the audit committee of the Company and the auditors of the Company.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company and are advised to refer to the details in the interim results announcement for the Reporting Period to be published by the Company before the end of August 2025.

By order of the Board of
China Resources Medical Holdings Company Limited
YU Hai
Chairman

PRC, August 1, 2025

As at the date of this announcement, the Board comprises Mr. YU Hai, Mr. SHAN Baojie and Ms. YANG Min as executive Directors; Ms. GE Lu as non-executive Director; Mr. WU Ting Yuk, Anthony, Mr. FU Tingmei, Mr. ZHOU Peng and Ms. LO Wing Sze as independent non-executive Directors.